Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study
Purpose: The impact of tramadol analgesic use before breast cancer diagnosis on survival in patients with chronic pain is unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the breast cancer-related survival of patients with chronic pain who received...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2022-03, Vol.12 (3), p.384 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 384 |
| container_title | Journal of personalized medicine |
| container_volume | 12 |
| creator | Sun, Mingyang Chang, Chia-Lun Lu, Chang-Yun Wu, Szu-Yuan Zhang, Jiaqiang |
| description | Purpose: The impact of tramadol analgesic use before breast cancer diagnosis on survival in patients with chronic pain is unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the breast cancer-related survival of patients with chronic pain who received long-term tramadol analgesic treatment with that of those who did not receive such treatment. Patients and Methods: We included patients with chronic pain and categorized them into two groups according to their analgesic use, comparing their breast cancer-related survival; patients with breast cancer and chronic pain who were prescribed ≥180 defined daily doses (DDDs) of tramadol analgesics per year >3 months before breast cancer diagnosis comprised the case group, and those who were prescribed non-tramadol analgesics before breast cancer diagnosis comprised the control group. Patients in both groups were matched at a ratio of 1:5. Results: The matching process yielded a final cohort of 624 patients (104 and 520 in the case and control groups, respectively) who were eligible for further analysis. According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratio for all-cause death in the case group compared with in the control group was 3.45 (95% confidence interval = 2.36−5.04; p < 0.001). Conclusion: Long-term tramadol analgesic use prior to breast cancer diagnosis might be associated with poor overall survival in patients with chronic pain compared with such patients that did not receive long-term tramadol analgesic treatment. |
| doi_str_mv | 10.3390/jpm12030384 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8951340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2644012289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-c4bbced31f7c380cd2ede922a48188546112bc4c760ba5df1659f292c392f1d43</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhkVpaUKaU-9F0EshuNWXv3ooJKYfgS1d2M1ZyLIca7E1riRv2d_RP1wtScO2c5lh5pmXGV6EXlPynvOafNjNE2WEE16JZ-ickTLPhGDF85P6DF2GsCMpqpyxgrxEZzznxxV-jn5vFr-3ezXi22lWOmLo8QrcfbY1fsJbrybVwYjvgsHg8I03KkTcKKeNxz14vFbRGhcD_mXjgJvBg7M6da37iK_x2sNsXLDxgDcavMm-q6gH0-E1zMuYVsFlNyqkRgMD-Ig3cekOr9CLXo3BXD7mC3T35fO2-Zatfny9ba5XmeZFGTMt2labjtO-1LwiumOmMzVjSlS0qnJRUMpaLXRZkFblXU-LvO5ZzTSvWU87wS_QpwfdeWkn0-n0h1ejnL2dlD9IUFb-O3F2kPewl1WdUy5IEnj3KODh52JClJMN2oyjcgaWIFkhBKGMVXVC3_6H7mDxLr13pJigVPAyUVcPlPYQgjf90zGUyKPf8sTvRL85vf-J_esu_wO6pqc6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642411437</pqid></control><display><type>article</type><title>Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sun, Mingyang ; Chang, Chia-Lun ; Lu, Chang-Yun ; Wu, Szu-Yuan ; Zhang, Jiaqiang</creator><creatorcontrib>Sun, Mingyang ; Chang, Chia-Lun ; Lu, Chang-Yun ; Wu, Szu-Yuan ; Zhang, Jiaqiang</creatorcontrib><description>Purpose: The impact of tramadol analgesic use before breast cancer diagnosis on survival in patients with chronic pain is unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the breast cancer-related survival of patients with chronic pain who received long-term tramadol analgesic treatment with that of those who did not receive such treatment. Patients and Methods: We included patients with chronic pain and categorized them into two groups according to their analgesic use, comparing their breast cancer-related survival; patients with breast cancer and chronic pain who were prescribed ≥180 defined daily doses (DDDs) of tramadol analgesics per year >3 months before breast cancer diagnosis comprised the case group, and those who were prescribed non-tramadol analgesics before breast cancer diagnosis comprised the control group. Patients in both groups were matched at a ratio of 1:5. Results: The matching process yielded a final cohort of 624 patients (104 and 520 in the case and control groups, respectively) who were eligible for further analysis. According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratio for all-cause death in the case group compared with in the control group was 3.45 (95% confidence interval = 2.36−5.04; p < 0.001). Conclusion: Long-term tramadol analgesic use prior to breast cancer diagnosis might be associated with poor overall survival in patients with chronic pain compared with such patients that did not receive long-term tramadol analgesic treatment.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm12030384</identifier><identifier>PMID: 35330383</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Analgesics ; Arthritis ; Breast cancer ; Cancer therapies ; Chemotherapy ; Chronic pain ; Cohort analysis ; Diabetic neuropathy ; Diagnosis ; Drug dosages ; Lymphatic system ; Medical diagnosis ; Medical prognosis ; Mortality ; Narcotics ; Nonsteroidal anti-inflammatory drugs ; Osteoarthritis ; Pain ; Patients ; Population studies ; Population-based studies ; Precision medicine ; Radiation therapy ; Regression analysis ; Survival ; Tramadol ; Urbanization ; Variables</subject><ispartof>Journal of personalized medicine, 2022-03, Vol.12 (3), p.384</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c367t-c4bbced31f7c380cd2ede922a48188546112bc4c760ba5df1659f292c392f1d43</cites><orcidid>0000-0001-5637-558X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951340/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951340/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35330383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Mingyang</creatorcontrib><creatorcontrib>Chang, Chia-Lun</creatorcontrib><creatorcontrib>Lu, Chang-Yun</creatorcontrib><creatorcontrib>Wu, Szu-Yuan</creatorcontrib><creatorcontrib>Zhang, Jiaqiang</creatorcontrib><title>Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study</title><title>Journal of personalized medicine</title><addtitle>J Pers Med</addtitle><description>Purpose: The impact of tramadol analgesic use before breast cancer diagnosis on survival in patients with chronic pain is unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the breast cancer-related survival of patients with chronic pain who received long-term tramadol analgesic treatment with that of those who did not receive such treatment. Patients and Methods: We included patients with chronic pain and categorized them into two groups according to their analgesic use, comparing their breast cancer-related survival; patients with breast cancer and chronic pain who were prescribed ≥180 defined daily doses (DDDs) of tramadol analgesics per year >3 months before breast cancer diagnosis comprised the case group, and those who were prescribed non-tramadol analgesics before breast cancer diagnosis comprised the control group. Patients in both groups were matched at a ratio of 1:5. Results: The matching process yielded a final cohort of 624 patients (104 and 520 in the case and control groups, respectively) who were eligible for further analysis. According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratio for all-cause death in the case group compared with in the control group was 3.45 (95% confidence interval = 2.36−5.04; p < 0.001). Conclusion: Long-term tramadol analgesic use prior to breast cancer diagnosis might be associated with poor overall survival in patients with chronic pain compared with such patients that did not receive long-term tramadol analgesic treatment.</description><subject>Age</subject><subject>Analgesics</subject><subject>Arthritis</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chronic pain</subject><subject>Cohort analysis</subject><subject>Diabetic neuropathy</subject><subject>Diagnosis</subject><subject>Drug dosages</subject><subject>Lymphatic system</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Narcotics</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Osteoarthritis</subject><subject>Pain</subject><subject>Patients</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Precision medicine</subject><subject>Radiation therapy</subject><subject>Regression analysis</subject><subject>Survival</subject><subject>Tramadol</subject><subject>Urbanization</subject><subject>Variables</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1r3DAQhkVpaUKaU-9F0EshuNWXv3ooJKYfgS1d2M1ZyLIca7E1riRv2d_RP1wtScO2c5lh5pmXGV6EXlPynvOafNjNE2WEE16JZ-ickTLPhGDF85P6DF2GsCMpqpyxgrxEZzznxxV-jn5vFr-3ezXi22lWOmLo8QrcfbY1fsJbrybVwYjvgsHg8I03KkTcKKeNxz14vFbRGhcD_mXjgJvBg7M6da37iK_x2sNsXLDxgDcavMm-q6gH0-E1zMuYVsFlNyqkRgMD-Ig3cekOr9CLXo3BXD7mC3T35fO2-Zatfny9ba5XmeZFGTMt2labjtO-1LwiumOmMzVjSlS0qnJRUMpaLXRZkFblXU-LvO5ZzTSvWU87wS_QpwfdeWkn0-n0h1ejnL2dlD9IUFb-O3F2kPewl1WdUy5IEnj3KODh52JClJMN2oyjcgaWIFkhBKGMVXVC3_6H7mDxLr13pJigVPAyUVcPlPYQgjf90zGUyKPf8sTvRL85vf-J_esu_wO6pqc6</recordid><startdate>20220302</startdate><enddate>20220302</enddate><creator>Sun, Mingyang</creator><creator>Chang, Chia-Lun</creator><creator>Lu, Chang-Yun</creator><creator>Wu, Szu-Yuan</creator><creator>Zhang, Jiaqiang</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5637-558X</orcidid></search><sort><creationdate>20220302</creationdate><title>Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study</title><author>Sun, Mingyang ; Chang, Chia-Lun ; Lu, Chang-Yun ; Wu, Szu-Yuan ; Zhang, Jiaqiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-c4bbced31f7c380cd2ede922a48188546112bc4c760ba5df1659f292c392f1d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Analgesics</topic><topic>Arthritis</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chronic pain</topic><topic>Cohort analysis</topic><topic>Diabetic neuropathy</topic><topic>Diagnosis</topic><topic>Drug dosages</topic><topic>Lymphatic system</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Narcotics</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Osteoarthritis</topic><topic>Pain</topic><topic>Patients</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Precision medicine</topic><topic>Radiation therapy</topic><topic>Regression analysis</topic><topic>Survival</topic><topic>Tramadol</topic><topic>Urbanization</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Mingyang</creatorcontrib><creatorcontrib>Chang, Chia-Lun</creatorcontrib><creatorcontrib>Lu, Chang-Yun</creatorcontrib><creatorcontrib>Wu, Szu-Yuan</creatorcontrib><creatorcontrib>Zhang, Jiaqiang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Mingyang</au><au>Chang, Chia-Lun</au><au>Lu, Chang-Yun</au><au>Wu, Szu-Yuan</au><au>Zhang, Jiaqiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study</atitle><jtitle>Journal of personalized medicine</jtitle><addtitle>J Pers Med</addtitle><date>2022-03-02</date><risdate>2022</risdate><volume>12</volume><issue>3</issue><spage>384</spage><pages>384-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>Purpose: The impact of tramadol analgesic use before breast cancer diagnosis on survival in patients with chronic pain is unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the breast cancer-related survival of patients with chronic pain who received long-term tramadol analgesic treatment with that of those who did not receive such treatment. Patients and Methods: We included patients with chronic pain and categorized them into two groups according to their analgesic use, comparing their breast cancer-related survival; patients with breast cancer and chronic pain who were prescribed ≥180 defined daily doses (DDDs) of tramadol analgesics per year >3 months before breast cancer diagnosis comprised the case group, and those who were prescribed non-tramadol analgesics before breast cancer diagnosis comprised the control group. Patients in both groups were matched at a ratio of 1:5. Results: The matching process yielded a final cohort of 624 patients (104 and 520 in the case and control groups, respectively) who were eligible for further analysis. According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratio for all-cause death in the case group compared with in the control group was 3.45 (95% confidence interval = 2.36−5.04; p < 0.001). Conclusion: Long-term tramadol analgesic use prior to breast cancer diagnosis might be associated with poor overall survival in patients with chronic pain compared with such patients that did not receive long-term tramadol analgesic treatment.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35330383</pmid><doi>10.3390/jpm12030384</doi><orcidid>https://orcid.org/0000-0001-5637-558X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2022-03, Vol.12 (3), p.384 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8951340 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Age Analgesics Arthritis Breast cancer Cancer therapies Chemotherapy Chronic pain Cohort analysis Diabetic neuropathy Diagnosis Drug dosages Lymphatic system Medical diagnosis Medical prognosis Mortality Narcotics Nonsteroidal anti-inflammatory drugs Osteoarthritis Pain Patients Population studies Population-based studies Precision medicine Radiation therapy Regression analysis Survival Tramadol Urbanization Variables |
| title | Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A24%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Impact%20of%20Long-Term%20Tramadol%20Use%20on%20Breast%20Cancer%20for%20Patients%20with%20Chronic%20Pain:%20A%20Propensity%20Score-Matched%20Population-Based%20Cohort%20Study&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Sun,%20Mingyang&rft.date=2022-03-02&rft.volume=12&rft.issue=3&rft.spage=384&rft.pages=384-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm12030384&rft_dat=%3Cproquest_pubme%3E2644012289%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642411437&rft_id=info:pmid/35330383&rfr_iscdi=true |